SCHEMBL5344962

SCHEMBL5344962

Nc1cccc(Nc2ccc([N+](=O)[O-])cc2C(=O)O)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 3/20 0.76
CTSL P07711 3/20 0.76
MAPT P10636 6/20 0.73
KMT2A Q03164 4/20 0.73
MEN1 O00255 3/20 0.73
AKR1C3 P42330 5/20 0.63
AKR1C2 P52895 5/20 0.63
MYC P01106 1/20 0.57
MAX P61244 1/20 0.57
MPO P05164 1/20 0.56
GFER P55789 1/20 0.56
ANO1 Q5XXA6 1/20 0.54
ANO2 Q9NQ90 1/20 0.54
GAA P10253 1/20 0.53
AKR1C4 P17516 1/20 0.53
AKR1C1 Q04828 1/20 0.53
ALDH1A1 P00352 1/20 0.50
CYP3A4 P08684 1/20 0.50
ALOX15 P16050 1/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354532 0.86 CTSV (1.00) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL5336704 0.85 CTSV (0.77) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL3026731 0.85 CTSV (0.76) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL3028534 0.85 CTSV (0.76) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL4249101 0.82 CTSV (0.86) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL10532509 0.82 CTSV (0.67) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL3033026 0.81 CTSV (0.76) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL7325216 0.81 MPO (0.83) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL3020950 0.81 MAPT (0.72) CTSVCTSLMAPTKMT2AMEN1
SCHEMBL19241672 0.81 MAPT (0.72) CTSVCTSLMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119390650-A Preparation method of diamine monomer containing acridone unit 东华大学 2025-02-07 CN disclosed
US-7300930-B2 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-27 US disclosed
US-7300930-B2 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-27 US disclosed
US-7300930-B2 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-27 US disclosed
US-7205311-B2 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED 2007-04-17 US disclosed
US-7160896-B2 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-01-09 US disclosed
US-7160896-B2 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-01-09 US disclosed
US-7160896-B2 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-01-09 US disclosed
US-20060111389-A1 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-05-25 US disclosed
EP-1363888-A2 THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS Cancer Research Technology Limited (GB) 2003-11-26 EP disclosed
US-20030207909-A1 Therapeutic acridone and acridine compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-11-06 US disclosed
WO-2002008193-A2 THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207909-A1 Therapeutic acridone and acridine compounds NAT1, TERT, CCNA1 CTSV 3412/4885CTSL 1904/4885MAPT 3949/4885
US-20060111389-A1 Therapeutic acridone and acridine compounds TERT, ACIN1, NAT1 CTSV 3330/4885CTSL 2241/4885MAPT 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.